Study how kidney findings change in Fabry disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study looks at the natural course of Fabry disease in the kidneys and how different kidney test results relate to each other. It may help doctors better understand kidney progression and treatment outcomes, including for people who have or have not had enzyme replacement therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Fabry disease
- You may be starting or have decided to get kidney-related tests (kidney biopsy, GFR, and urine albumin) OR you’ve already had similar tests in past studies
- Your kidney tests must be part of a clinical plan or prior study, not only newly ordered for the study
- You do not have another kidney disease besides Fabry
- Your blood creatinine is not higher than 2.5 mg/dL (based on lab testing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to look at how Fabry disease affects the kidneys, including scarring, swelling, and oxygen levels. It may help researchers understand kidney problems better and find new ways to monitor the disease.
This trial tests if enzyme replacement therapy works well and is safe for Fabry disease. It is for people who are already prescribed this treatment.
This study checks whether certain heart-related blood tests and heart scans can help monitor people with Fabry disease. It may be useful for both people who have never received enzyme replacement therapy and those who have.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.